BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

BrainStorm Cell Therapeutics (NASDAQ:BCLI) CMO Dr. Ralph Kern sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Upcoming Events

Jan 13-15, 2020
April 27-29, 2020
May 18-20, 2020
July 13-15, 2020